Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 240

1.

Brentuximab vedotin in Hodgkin's lymphoma.

Pro B, Perini GF.

Expert Opin Biol Ther. 2012 Oct;12(10):1415-21. doi: 10.1517/14712598.2012.718328. Epub 2012 Aug 31. Review.

PMID:
22937794
2.

Brentuximab Vedotin in CD30+ Lymphomas.

Perini GF, Pro B.

Biol Ther. 2013;3:15-23. Epub 2013 Mar 1. Review.

3.

Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.

Chen R, Chen B.

Drug Des Devel Ther. 2015 Mar 23;9:1729-33. doi: 10.2147/DDDT.S82007. eCollection 2015. Review.

4.

CD30 as a therapeutic target for lymphoma.

Schirrmann T, Steinwand M, Wezler X, Ten Haaf A, Tur MK, Barth S.

BioDrugs. 2014 Apr;28(2):181-209. doi: 10.1007/s40259-013-0068-8. Review.

PMID:
24043362
5.

Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma?

Goyal SD, Bartlett NL.

Curr Hematol Malig Rep. 2012 Sep;7(3):179-85. doi: 10.1007/s11899-012-0126-1. Review.

PMID:
22669711
6.

Brentuximab vedotin in systemic T-cell lymphoma.

Oki Y, Younes A.

Expert Opin Biol Ther. 2012 May;12(5):623-32. doi: 10.1517/14712598.2012.670216. Epub 2012 Mar 20.

PMID:
22428917
7.

Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.

Newland AM, Li JX, Wasco LE, Aziz MT, Lowe DK.

Pharmacotherapy. 2013 Jan;33(1):93-104. doi: 10.1002/phar.1170. Review.

PMID:
23307550
8.

Brentuximab vedotin for the treatment of CD30+ lymphomas.

Foyil KV, Bartlett NL.

Immunotherapy. 2011 Apr;3(4):475-85. doi: 10.2217/imt.11.15. Review.

PMID:
21463188
9.

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R.

J Clin Oncol. 2012 Jun 20;30(18):2183-9. doi: 10.1200/JCO.2011.38.0410. Epub 2012 Mar 26.

10.

Anti-CD30 Antibodies for Hodgkin lymphoma.

Foyil KV, Bartlett NL.

Curr Hematol Malig Rep. 2010 Jul;5(3):140-7. doi: 10.1007/s11899-010-0053-y. Review.

PMID:
20446121
11.

Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.

Gualberto A.

Expert Opin Investig Drugs. 2012 Feb;21(2):205-16. doi: 10.1517/13543784.2011.641532. Epub 2011 Nov 30. Review.

PMID:
22127011
12.

Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma.

Haddley K.

Drugs Today (Barc). 2012 Apr;48(4):259-70. doi: 10.1358/dot.2012.48.4.1788435. Review.

PMID:
22536568
13.

Brentuximab vedotin in anaplastic large cell lymphoma.

Skarbnik AP, Smith MR.

Expert Opin Biol Ther. 2012 May;12(5):633-9. doi: 10.1517/14712598.2012.673578. Epub 2012 Mar 27.

PMID:
22449148
14.

Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma.

Vaklavas C, Forero-Torres A.

Ther Adv Hematol. 2012 Aug;3(4):209-25. doi: 10.1177/2040620712443076.

15.

Brentuximab vedotin: an anti-CD30 antibody-drug conjugate.

Bradley AM, Devine M, DeRemer D.

Am J Health Syst Pharm. 2013 Apr 1;70(7):589-97. doi: 10.2146/ajhp110608. Review.

PMID:
23515511
16.

Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.

Forero-Torres A, Fanale M, Advani R, Bartlett NL, Rosenblatt JD, Kennedy DA, Younes A.

Oncologist. 2012;17(8):1073-80. doi: 10.1634/theoncologist.2012-0133. Epub 2012 Aug 1.

17.

Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.

Chen X, Soma LA, Fromm JR.

Onco Targets Ther. 2013 Dec 19;7:45-56. doi: 10.2147/OTT.S39107. Review.

18.

Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.

Ogura M, Tobinai K, Hatake K, Ishizawa K, Uike N, Uchida T, Suzuki T, Aoki T, Watanabe T, Maruyama D, Yokoyama M, Takubo T, Kagehara H, Matsushima T.

Cancer Sci. 2014 Jul;105(7):840-6. doi: 10.1111/cas.12435. Epub 2014 Jul 1.

19.

Brentuximab vedotin for the treatment of Hodgkin's lymphoma.

Pham A, Chen R.

Expert Rev Hematol. 2015 Aug;8(4):403-12. doi: 10.1586/17474086.2015.1044432. Epub 2015 May 12. Review.

PMID:
25967932
20.

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.

Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, Advani R, Matous JV, Ramchandren R, Rosenblatt JD, Huebner D, Levine P, Grove L, Forero-Torres A.

J Hematol Oncol. 2014 Mar 19;7:24. doi: 10.1186/1756-8722-7-24.

Items per page

Supplemental Content

Write to the Help Desk